Statistically significant and clinically meaningful improvements in overall survival (OS), a crucial secondary endpoint, were seen with AstraZeneca’s Tagrisso (osimertinib) compared to placebo in the adjuvant treatment of patients with early-stage (IB, II, and IIIA) epidermal growth factor receptor-mutated (EGFRm)…
Tag: Astrazeneca
We at AstraZeneca are committed to providing a great workplace. Where you have the freedom to advance scientific knowledge and unleash your entrepreneurial energy. There is no greater place to impact society, medicine, and patients. a welcoming environment that values…